RogerioLilenbaumMD

Oncology • Jupiter, FL

Chief Physician Executive

Join to view full profile

Dr. Lilenbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lilenbaum's full profile

Already have an account?

Office
1210 S. Dixie Hwy,
Jupiter, FL 33458

Summary

Dr. Rogerio Lilenbaum is the Chief Physician Executive of Jupiter Medical Center in Jupiter, FL. He received his medical degree from the Federal University of Rio de Janeiro and completed his training at Washington University in St Louis and at the University of California San Diego. He specializes in thoracic oncology.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1991 - 1992
Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1986

Certifications & Licensure

CA State Medical License 1992 - Present
FL State Medical License 1996 - 2025
AZ State Medical License 2020 - 2024
CT State Medical License 2013 - 2020
MD State Medical License 1995 - 1998

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:South Florida Castle Connolly, 2012
Gulfstream FL-Broward Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Fellow (FACP) American College of Physicians, 2002
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 1997 Oct 01
Completed
Phase 3
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
L-Arginine Supplements in Treating Women Who Are Cancer Survivors Start of enrollment: 2007 May 01
Completed
Not Applicable
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Start of enrollment: 2008 Mar 01
Completed
Phase 2
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2003 Sep 01
Completed
Phase 2
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Trial of Poor Performance Status Patients (ToPPS) Start of enrollment: 2009 Jun 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

37 citations
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
Sarah B. Goldberg, Mary W. Redman, Rogerio Lilenbaum, Katerina Politi, Thomas E. Stinchcombe
Journal of Clinical Oncology. 2020-10-06
312 citations
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B. Goldberg, Kurt A. Schalper, Scott N. Gettinger, Amit Mahajan, Roy S. Herbst
The Lancet. Oncology. 2020-05-01
9 citations
Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction
Anne C. Chiang, Jessica Lake, Naralys Sinanis, Debra S. Brandt, Jane Kanowitz
Journal of Oncology Practice. 2018-12-11

Other

Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status
Lilenbaum RC
http://www.uptodate.com/contents/systemic-therapy-for-advanced-non-small-cell-lung-cancer-in-elderly
UpToDate, Wolters Kluwer Health - 2012-12-18
Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy
Lilenbaum RC
http://www.uptodate.com/contents/advanced-non-small-cell-lung-cancer-maintenance-therapy-after-initi
UpToDate, Wolters Kluwer Health - 2013-01-10
Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene
Lilenbaum RC
http://www.uptodate.com/contents/initial-systemic-chemotherapy-for-advanced-non-small-cell-lung-canc
UpToDate, Wolters Kluwer Health - 2013-02-12
Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor
Lilenbaum RC
http://www.uptodate.com/contents/initial-systemic-therapy-for-advanced-non-small-cell-lung-cancer-wi
UpToDate, Wolters Kluwer Health - 2013-03-20
Overview of the treatment of advanced non-small cell lung cancer
Lilenbaum RC
http://www.uptodate.com/contents/overview-of-the-treatment-of-advanced-non-small-cell-lung-cancer
UpToDate, Wolters Kluwer Health - 2013-02-13
Second-line therapy for patients with previously treated advanced non-small cell lung cancer
Lilenbaum RC
http://www.uptodate.com/contents/second-line-therapy-for-patients-with-previously-treated-advanced-n
UpToDate, Wolters Kluwer Health - 2013-01-10
Systemic therapy for poor performance status patients with advanced non-small cell lung cancer
Lilenbaum RC
http://www.uptodate.com/contents/systemic-therapy-for-poor-performance-status-patients-with-advanced
UpToDate, Wolters Kluwer Health - 2012-06-29
Join now to see all

Press Mentions

Jupiter Medical Center Targets Prostate Cancer with PSMA PET-CT ScansJanuary 11th, 2023
Anderson Family Cancer Institute Offering Next-Day Appointments, Cutting-Edge TreatmentsJanuary 1st, 2023
Managing Cancer Care During COVID-19: 4 Oncologists Weigh InJuly 22nd, 2020
Join now to see all